BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21866466)

  • 21. Systemic mastocytosis associated with essential thrombocythemia.
    Dobrea C; Ciochinaru M; Găman A; Dănăilă E; Coriu D
    Rom J Morphol Embryol; 2012; 53(1):197-202. PubMed ID: 22395523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis.
    Hahn HP; Hornick JL
    Am J Surg Pathol; 2007 Nov; 31(11):1669-76. PubMed ID: 18059223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct clonal origins of systemic mastocytosis and associated B-cell lymphoma.
    Kim Y; Weiss LM; Chen YY; Pullarkat V
    Leuk Res; 2007 Dec; 31(12):1749-54. PubMed ID: 17544505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis.
    Reichard KK; Chen D; Pardanani A; McClure RF; Howard MT; Kurtin PJ; Wood AJ; Ketterling RP; King RL; He R; Morice WG; Hanson CA
    Am J Clin Pathol; 2015 Sep; 144(3):493-502. PubMed ID: 26276780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR.
    Schumacher JA; Elenitoba-Johnson KS; Lim MS
    J Clin Pathol; 2008 Jan; 61(1):109-14. PubMed ID: 17526803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
    Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
    Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
    Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
    Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How I treat patients with advanced systemic mastocytosis.
    Valent P; Sperr WR; Akin C
    Blood; 2010 Dec; 116(26):5812-7. PubMed ID: 20855864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers.
    Horny HP; Sotlar K; Stellmacher F; Krokowski M; Agis H; Schwartz LB; Valent P
    J Clin Pathol; 2006 Mar; 59(3):298-302. PubMed ID: 16505282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
    Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
    Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mastocytosis.
    Metcalfe DD
    Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.
    Yoshida C; Takeuchi M; Tsuchiyama J; Sadahira Y
    Intern Med; 2009; 48(22):1973-8. PubMed ID: 19915299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.
    Wang SA; Hutchinson L; Tang G; Chen SS; Miron PM; Huh YO; Jones DM; Bueso-Ramos C; Verstovsek S; Medeiros LJ; Miranda RN
    Am J Hematol; 2013 Mar; 88(3):219-24. PubMed ID: 23440662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "Occult" mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis.
    Sotlar K; Saeger W; Stellmacher F; Stahmer J; Jäckle S; Valent P; Horny HP
    J Clin Pathol; 2006 Aug; 59(8):875-8. PubMed ID: 16873565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hodgkin's lymphoma is a rare form of clonal haematological non-mast cell disease in systemic mastocytosis.
    Gasljevic G; Grcar-Kuzmanov B; Grosel A; Sever M; Gazic B; Kloboves-Prevodnik V
    Diagn Pathol; 2015 Mar; 10():5. PubMed ID: 25881198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens.
    Sotlar K; Horny HP; Simonitsch I; Krokowski M; Aichberger KJ; Mayerhofer M; Printz D; Fritsch G; Valent P
    Am J Surg Pathol; 2004 Oct; 28(10):1319-25. PubMed ID: 15371947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis.
    Teodosio C; García-Montero AC; Jara-Acevedo M; Sánchez-Muñoz L; Pedreira CE; Álvarez-Twose I; Matarraz S; Morgado JM; Bárcena P; Matito A; Mayado A; Sanchez ML; Diez-Campelo M; Escribano L; Orfao A
    J Allergy Clin Immunol; 2013 Apr; 131(4):1213-24, 1224.e1-4. PubMed ID: 23403045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
    Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
    Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.